- Archives
-
-
-
-
-
-
-
-
-
-
Discussing biocompatibility methodology and outsourcing
D. Keith Goins, Ph.D.
Is there a workable high-growth business model?
Daniel D. Adams
How has genomics and proteomics altered the chemistry outsourcing arena?
Gil Y. Roth
How will the rise of specialist intermediary organizations affect the process?
David Cavalla, MA, Ph.D.
When will we see legal generics of top biopharmaceuticals?
Dr. Enrico T. Polastro
Understanding 21CFR11: How to make sense of the rules on electronic data
Carol Brandt
As biopharmaceuticals gain FDA approval, where will supply come from?
Sandra Fox, Lynne Sopchak, Ph.D., and Richard Khoury, Ph.D.
What to consider when outsourcing this pivotal aspect of drug development
Timothy D.J. Halls, Ph.D.
How to choose an effective regulatory partner
Evan B. Siegel, Ph.D., and Eri
Read the results of Contract Pharma's annual salary survey, as well as reports from other organizations
Gil Roth
Will a supply crunch hurt this growing market?
Gil Y. Roth
Technology can trim clinical trial timeframes
Paul Bleicher, M.D., Ph.D
Continuing a series on 21CFR11 compliance
Kevin Lloyd
It's as much about defining expectations as it is about science, testing and data
Andrew R. Ginsberg
A pharmaceutical industry purchasing manager's perspective
Martin H. Joyce
Effective project planning makes all the difference
Joseph Saccomanno
A sponsor discusses the benefits of moving outsourcing earlier in the value chain
Anthony De Stefano
Making the transition from a traditional model to a technology-based drug discovery service partner
John L. Flavin, Constance S. Cassidy, Ph.D., Sara Moran, Ph.D., and Ben Schiltz
A sponsor's guide to the audit process
Shamik Pandit and Marcia Gartzke
21CFR11 enables use of electronic records and signatures, but it requires a comprehensive validation program
Kevin Lloyd
Should sponsors designate an employee to stay on site at a CMO?
Thomas E. Handel
A new web site helps solve the packaging puzzle
Sarah W. Madley
|
